Table A32Incremental costs and effectiveness by treatment strategy for non-Hodgkin lymphoma patients (using a baseline risk of neutropenic sepsis for one course of chemotherapy of 44.22%)

StrategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£) versus baseline
(QALYs)		ICER (£) incremental
(QALYs)
Nothing/Placebo£729.2-3.3*10-3——ComparatorComparator
Secondary prophylaxis with PEG-G-CSF£1,510.7-2.9*10-3£781.46.7*10-4£1.2 million£1.2 million
Secondary prophylaxis with G(M)-CSF£1,629.0-2.6*10-3£899.73.2*10-4£2.8 millionDominated
Primary prophylaxis with PEG-G-CSF£4,238.1-2.1*10-3£3,508.92.2*10-3£1.6 million£1.8 million
Primary prophylaxis with G(M)-CSF£5,242.0-1.1*10-3£4,512.81.1*10-3£4.1 millionDominated

From: Appendix A, A cost-utility analysis of primary and secondary prophylaxis with G(M)-CSF and/or quinolones for the prevention of neutropenic sepsis

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.